LIH Neuro-Oncology Researchers Support International Study Opening New Possibilities for Personalised Brain Cancer Treatment

LIH Neuro-Oncology Researchers Support International Study Opening New Possibilities for Personalised Brain Cancer Treatment

(IN BRIEF) Researchers from the Luxembourg Institute of Health’s NORLUX Neuro-Oncology Laboratory have contributed to an international study published in Nature that sheds new light on how adult brain tumours, particularly IDH-mutant gliomas, evolve and become more aggressive after treatment. The study analysed tumour samples from 35 patients collected at different stages of disease using advanced genomic and single-cell technologies, revealing that recurrent tumours often contain more immature and rapidly dividing cancer cells. Researchers also identified multiple biological routes driving tumour progression, including genetic alterations in cancer cells and interactions with the tumour environment. The LIH NORLUX team contributed rare longitudinal tumour samples through the PRECISION-PDX cohort and performed functional investigations in matched patient-derived preclinical models to validate predictions from single-cell analyses. The findings provide an important resource for brain cancer research and could support more personalised treatment strategies, including further investigation into whether IDH inhibitors should be used before chemotherapy and radiotherapy in selected cases.

(PRESS RELEASE) LUXEMBOURG, 8-Jun-2026 — /EuropaWire/ — Researchers from the Luxembourg Institute of Health have contributed to a major international study published in Nature that provides new insight into how adult brain tumours evolve, recur and become more resistant to treatment over time.

The study focuses on IDH-mutant gliomas, a type of brain tumour that often affects younger and middle-aged adults. Although existing therapies can slow the progression of the disease, these tumours almost always return. Until now, the biological changes that occur as the disease advances have remained only partly understood.

An international consortium analysed tumour samples collected from 35 patients at different stages of their disease. Using advanced genomic and single-cell technologies, the researchers examined how the tumours changed over time and identified mechanisms that allow them to become more aggressive following treatment.

The findings show that recurrent tumours often contain a higher proportion of immature, fast-dividing cancer cells. The researchers also identified several pathways that contribute to tumour progression, including genetic changes within cancer cells and interactions between the tumour and its surrounding environment. Together, the results offer one of the clearest views so far of how IDH-mutant gliomas evolve and why they remain difficult to treat.

The NORLUX Neuro-Oncology Laboratory at the Luxembourg Institute of Health played an important role in the research. The team contributed rare longitudinal tumour samples from patients with IDH-mutant gliomas through the PRECISION-PDX cohort, enabling the consortium to follow tumour evolution across time. NORLUX also carried out functional investigations using matched patient-derived preclinical models, which helped validate predictions generated from single-cell analyses.

“This study demonstrates that glioma recurrence can arise via multiple biological routes. By combining rare patient samples, advanced single-cell technologies, and clinically relevant models, we were able to better understand how these tumours adapt and evolve. This knowledge will be essential for developing more precise and effective therapies,” said Dr Anna Golebiewska, Head of the NORLUX Lab at the LIH and co-author of the paper.

The publication underlines the importance of international scientific collaboration in tackling complex cancers and provides a valuable resource for researchers working to improve outcomes for patients with brain tumours. It also offers new perspectives on treatment sequencing, showing that while chemotherapy and radiotherapy remain essential approaches that can extend survival, the timing of different therapies may be critical.

The study supports further investigation into whether specific IDH inhibitors could be used before chemotherapy and radiotherapy, with those established treatments potentially reserved for later stages of the disease. This could open new possibilities for more personalised treatment strategies based on how individual tumours evolve.

The research received support from the Luxembourg National Research Fund through the GLASSLUX and PLASTIG projects, including FNR grants C20/BM/14646004/GLASSLUX and INTER/TRANSCAN22/17612718/PLASTIG.

Through its contribution to the study, the LIH NORLUX Neuro-Oncology Laboratory has helped advance understanding of brain tumour evolution and the biological processes that drive recurrence, aggressiveness and treatment resistance in IDH-mutant gliomas.

Media Contact:

Anna Golebiewska
Group Head
NORLUX Neuro-Oncology Laboratory

SOURCE: Luxembourg Institute of Health